CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer
-
- STATUS
- Recruiting
-
- End date
- Jan 31, 2024
-
- participants needed
- 279
-
- sponsor
- Regeneron Pharmaceuticals
Summary
CMP-001-009 is a Phase 2 study of intratumoral CMP-001 in combination with an intravenous PD-1-blocking antibody administered to participants with certain types of advanced or metatastic cancer.
The primary objective of the study is to determine the Investigator-assessed confirmed objective response with CMP-001 in combination with a programmed cell death protein (PD-1)-blocking antibody in subjects with certain types of advanced or metatastic cancer.
The secondary objectives are to:
- To evaluate the safety and tolerability of CMP-001 administered by intratumoral (IT) injection in combination with a PD-1-blocking antibody in study subjects.
- To evaluate the efficacy of CMP-001 in combination with a PD-1-blocking antibody in study subjects.
Participants will continue to receive treatment of CMP-001 in combination with a PD-1-blocking antibody according to the treatment schedule until a reason for treatment discontinuation is reached.
Description
Former Sponsor Checkmate Pharmaceuticals
Details
| Condition | Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Metastatic Cancer, Triple Negative Breast Cancer, Advanced Cancer |
|---|---|
| Treatment | CMP-001, Cemiplimab-Rwlc |
| Clinical Study Identifier | NCT04916002 |
| Sponsor | Regeneron Pharmaceuticals |
| Last Modified on | 4 October 2022 |
Eligibility
How to participate?
,
You have contacted , on
Your message has been sent to the study team at ,
What happens next?
- You can expect the study team to contact you via email or phone in the next few days.
- Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.
You are contacting
Primary Contact
Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.
Learn moreIf you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Learn moreComplete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.
Learn moreSimilar trials to consider
Browse trials for
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteer